Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EPS (Weighted Average and Diluted) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.84 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 162.22% year-over-year to -$0.84; the TTM value through Dec 2025 reached -$3.42, up 91.19%, while the annual FY2025 figure was -$3.43, 40.96% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.84 in Q4 2025 for Artiva Biotherapeutics, up from -$0.88 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.62 in Q3 2023 and bottomed at -$22.0 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$6.33, with a median of -$0.88 recorded in 2025.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 109.07% in 2024 and then tumbled 162.22% in 2025.
  • Artiva Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$14.89 in 2023, then surged by 109.07% to $1.35 in 2024, then crashed by 162.22% to -$0.84 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.84, -$0.88, and -$0.87 for Q4 2025, Q3 2025, and Q2 2025 respectively.